Hirotsu Bio Science

About:

Hirotsu Bio Science develops a biodiagnostic technology to help in the early detection of cancer.

Website: https://hbio.jp

Twitter/X: HIROTSU_BIO

Top Investors: SBI Investment, Future Venture Capital, Dai-ichi Life, Shinkin Capital, Horipro

Description:

Founded in 2016 by Takaaki Hirotsu, Hirotsu Bio Science leads the Multi-Cancer Early Detection market in Japan, serving 600,000 customers at a highly accessible $150 retail price point. Recognized globally for commercializing the world's first bio-diagnostic, Hirotsu leverages the natural capabilities of selected microorganisms while also enhancing them with genetic engineering and modern bioinformatics. The technology is backed by clinical research conducted with top hospitals in Japan and published in prominent peer-reviewed journals. The result is a urine-based, highly sensitive, and ultra-affordable cancer risk assessment with extremely compelling health economics. Currently operational at scale, we serve 20,000 customers per month and are uniquely capable of detecting the elusive early Stages 0 and I Cancers. Our mission is to make early cancer detection the standard, not the exception, in patient care.